

Acadia Pharmaceuticals Inc. is providing this letter in response to your unsolicited request for medical information. It is for scientific-exchange and individual educational purposes only, and should not be copied or distributed. Information included in this letter may not be consistent with the US FDA-approved Prescribing Information for NUPLAZID® (pimavanserin) or may be related to unapproved uses of NUPLAZID. This letter is not intended to advocate any unapproved or approved use, indication, dosage, or other treatment-related decision. Acadia strives to provide current, accurate, and fair-balanced information in compliance with current industry information dissemination guidelines.

For further information regarding Indication, **Boxed WARNING** and other Important Safety Information for NUPLAZID, please click here: <u>Prescribing Information</u>.



NUPLAZID® (pimavanserin): Individual Domains of the SAPS-PD used in Parkinson's Disease Psychosis Pivotal Study

This letter is provided in response to your specific request for information regarding the outcomes for the individual domains of the Parkinson's disease (PD)-adapted Scale for the Assessment of Positive Symptoms (SAPS-PD) from the pimavanserin pivotal study in PD psychosis.

Summary

- In a <u>supportive analysis</u> of the pivotal Phase 3 study of pimavanserin in participants with hallucinations and delusions associated with PD psychosis (N=199), an effect was seen on both the hallucinations and delusions components of the SAPS-PD.¹
- For the **SAPS-PD Hallucinations domain**, the auditory (H1), visual (H6), and global (H7) items were the main contributors to the score change from baseline.²
- For the <u>SAPS-PD Delusions domain</u>, the persecutory (D1) item was the main contributor to the score change from baseline.²

Pivotal Phase 3 Study (ACP-103-020)

ACP-103-020 was a randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of pimavanserin 34 mg in 199 adult participants with hallucinations and delusions associated with PD psychosis.³ Study participants had a diagnosis of PD (with or without dementia) established at least 1 year prior to study entry and had psychotic symptoms (hallucinations and/or delusions) that started after the PD diagnosis, were present for at least one month, and were severe and frequent enough to warrant treatment with an antipsychotic. Participants were allowed to be on dopaminergic medications but were required to be on a stable dose for one month prior to baseline. Primary efficacy was evaluated based on change from baseline to Day 43 (Week 6) in the SAPS-PD total score.^{1,3}

Following a 2-week nonpharmacological lead-in period, participants were randomized to receive pimavanserin 34 mg/day (N=105) or placebo (N=94). Of those, 185 participants (95 in the pimavanserin arm and 90 in the placebo arm) met the requirements to be included in the full analysis.³

Baseline Characteristics

Baseline demographics and clinical characteristics were similar between the two groups. Among the 185 participants, the mean age was 72 years (**Table 1**). The majority of participants were male (63%) and white (95%). The SAPS-PD score at baseline was 14.7 (standard deviation [SD] 5.55) and 15.9 (6.12) in the placebo and pimavanserin arms, respectively.³



Table 1. Selected Baseline Characteristics (Full Analysis Set)³

| | Placebo (n=90) | Pimavanserin (n=95) |
|--|-------------------|------------------------|
| Age, years | 72.4 (7.92) | 72.4 (6.55) |
| Sex, female | 38 (42%) | 31 (33%) |
| Ethnic group, white | 85 (94%) | 90 (95%) |
| Body-mass index, kg/m² | 26.4 (5.65) | 26.2 (4.57) |
| MMSE score | 26.6 (2.40) | 26.0 (2.61) |
| Time since first PD psychosis symptoms, months | 36.4 (39.57) | 30.9 (30.01) |
| SAPS-PD | 14.7 (5.55) | 15.9 (6.12) |
| CGI-S | 4.32 (0.91) | 4.27 (0.92) |

Data are mean (SD) or n (%). The full analysis set consisted of all patients who received ≥ 1 dose and had SAPS assessments at baseline and ≥ 1 post-baseline.

Abbreviations: CGI-S=Clinical Global Impression-Severity; MMSE=Mini-Mental State Examination; PD=Parkinson's disease; SAPS=Scale for the Assessment of Positive Symptoms; SAPS-PD=PD-adapted Scale for the Assessment of Positive Symptoms; SD=standard deviation.

Results

Primary Efficacy

Participants in the pimavanserin 34 mg group experienced a statistically significant improvement in SAPS-PD scores from baseline to Day 43 compared with placebo (-5.79 vs. -2.73). The treatment difference (pimavanserin minus placebo) was -3.06 (95% confidence interval [CI], -4.91 to -1.20; p=0.0014). Although the primary endpoint was at Day 43, a statistically significant difference between pimavanserin and placebo was observed as early as Day 29 (p=0.0369).

Supportive Efficacy

An effect was seen on both the hallucinations and delusions components of the SAPS-PD (**Table 2**).¹

Table 2. Change from Baseline to Day 43 in SAPS-PD Hallucinations and Delusions Components (N=185)¹

| Endpoint | Treatment group | Mean baseline score (SD) | LSM change from baseline (SE) | Placebo-subtracted difference* (95% CI) |
|-----------------------------|-----------------|-----------------------------|-------------------------------|---|
| SAPS-PD | Pimavanserin | 11.1 (4.58) | -3.81 (0.46) | 2.01 (2.20 , 0.72) |
| Hallucinations [†] | Placebo | 10.0 (3.80) | -1.80 (0.46) | -2.01 (-3.29, -0.72) |
| SAPS-PD | Pimavanserin | 4.8 (3.59) | -1.95 (0.32) | 0.04 (1.92 0.04) |
| Delusions [†] | Placebo | 4.8 (3.82) | -1.01 (0.32) | -0.94 (-1.83, -0.04) |

^{*}Difference (drug minus placebo) in least-squares mean change from baseline.

Abbreviations: CI=confidence interval; LSM=least squares mean; SAPS-PD=PD-adapted Scale for the Assessment of Positive Symptoms; SD=standard deviation; SE=standard error.

Table 3 summarizes the score changes from baseline to Day 43 for individual items in the SAPS-PD Hallucinations domain.² The auditory (H1), visual (H6), and global (H7) items were the main contributors to the score change from baseline in the SAPS-PD Hallucinations domain.

[†]Supportive analysis.



Table 3. Hallucinations Domain: SAPS-PD Individual Item Score Change from Baseline to Day 43 (OC, MMRM; ITT Analysis Set*)²

| Item | Treatment group | Mean baseline score (SD) | LSM change from baseline (SE) | Placebo-subtracted difference [†] (95% CI) |
|--|--------------------|--------------------------|-------------------------------|--|
| H1 - Auditory hallucinations | Pimavanserin | 1.7 (1.86) | -0.64 (0.16) | -0.56 (-1.01, -0.11) |
| | Placebo | 1.0 (1.48) | -0.08 (0.16) | -0.30 (-1.01, -0.11) |
| H3 - Voices conversing | Pimavanserin | 1.1 (1.73) | -0.29 (0.12) | 0.09 (-0.24, 0.43) |
| | Placebo | 0.5 (1.18) | -0.38 (0.12) | |
| H4 - Somatic or tactile | Pimavanserin | 0.7 (1.28) | -0.31 (0.09) | -0.00 (-0.24, 0.24) |
| hallucinations | Placebo | 0.6 (1.43) | -0.30 (0.09) | |
| H6 - Visual hallucinations | Pimavanserin | 3.9 (1.39) | -1.31 (0.18) | -0.61 (-1.12, -0.11) |
| | Placebo | 4.1 (1.32) | -0.69 (0.18) | -0.01 (-1.12, -0.11) |
| H7 - Global rating of severity of hallucinations | Pimavanserin | 3.8 (0.96) | -1.16 (0.15) | 0.66 (1.09 .0.25) |
| | Placebo | 3.7 (1.04) | -0.50 (0.15) | -0.66 (-1.08, -0.25) |

^{*95} participants in the pimavanserin arm, and 90 in the placebo arm.

Abbreviations: CI=confidence interval; ITT=intent-to-treat; LSM=least squares mean; MMRM=mixed model repeated measures analysis; OC=observed cases; SAPS-PD=PD-adapted Scale for the Assessment of Positive Symptoms; SD=standard deviation; SE=standard error.

Table 4 summarizes the score changes from baseline to Day 43 for items in the SAPS-PD Delusions domain.² The persecutory (D1) item contributes the bulk of the change from baseline score of the SAPS-PD Delusions domain.

Table 4. Delusions Domain: SAPS-PD Individual Item Score Change from Baseline to Day 43 (OC, MMRM; ITT Analysis Set*)²

| Item | Treatment group | Mean baseline score (SD) | LSM change from baseline (SE) | Placebo-subtracted difference [†] (95% CI) |
|--|--------------------|--------------------------|-------------------------------|--|
| D1 - Persecutory delusions | Pimavanserin | 1.4 (1.63) | -0.66 (0.14) | -0.50 (-0.89, -0.10) |
| | Placebo | 1.2 (1.57) | -0.16 (0.14) | |
| D2 - Delusions of jealousy | Pimavanserin | 0.5 (1.09) | -0.31 (0.07) | -0.17 (-0.37, 0.04) |
| | Placebo | 0.6 (1.19) | -0.14 (0.07) | |
| D7 - Ideas and delusions of reference | Pimavanserin | 0.3 (0.96) | -0.20 (0.08) | -0.03 (-0.24, 0.19) |
| | Placebo | 0.5 (1.15) | -0.17 (0.08) | -0.03 (-0.24, 0.19) |
| D13 - Global rating of severity of delusions | Pimavanserin | 2.5 (1.61) | -0.80 (0.15) | -0.27 (-0.68, 0.14) |
| | Placebo | 2.5 (1.55) | -0.53 (0.15) | -0.27 (-0.06, 0.14) |

^{*95} participants in the pimavanserin arm, and 90 in the placebo arm.

Abbreviations: CI=confidence interval; ITT=intent-to-treat; LSM=least squares mean; MMRM=mixed model repeated measures analysis; OC=observed cases; SAPS-PD=PD-adapted Scale for the Assessment of Positive Symptoms; SD=standard deviation; SE=standard error.

References

- 1. NUPLAZID[®] (pimavanserin) [package insert]. San Diego, CA. Acadia Pharmaceuticals Inc. [Link]
- 2. Acadia Pharmaceuticals Inc. Data on File. ACP-103-020 SAPS-PD Individual Item Analysis. 2016.
- 3. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *Lancet*. 2014;383(9916):533-540. [PubMed]

[†]Difference (drug minus placebo) in LSM change from baseline.

[†]Difference (drug minus placebo) in LSM change from baseline.